Literature DB >> 14615655

Grade 4 events are as important as AIDS events in the era of HAART.

Ronald B Reisler1, Cong Han, William J Burman, Ellen M Tedaldi, James D Neaton.   

Abstract

OBJECTIVE: To estimate incidence and predictors of serious or life-threatening events that are not AIDS defining, AIDS events, and death among patients treated with highly active antiretroviral therapy (HAART) in the setting of 5 large multicenter randomized treatment trials conducted in the United States.
METHODS: Data were analyzed from 2,947 patients enrolled from December 1996 through December 2001. All patients were to receive antiretrovirals throughout follow-up. Data collection was uniform for all main outcome measures: serious or life-threatening (grade 4) events, AIDS, and death.
RESULTS: During follow-up, 675 patients experienced a grade 4 event (11.4 per 100 person-years); 332 developed an AIDS event (5.6 per 100 person-years); and 272 died (4.6 per 100 person-years). The most common grade 4 events were liver related (148 patients, 2.6 per 100 person-years). Cardiovascular events were associated with the greatest risk of death (hazard ratio = 8.64; 95% CI: 5.1 to 14.5). The first grade 4 event and the first AIDS event were associated with similar risks of death, 5.68 and 6.95, respectively.
CONCLUSIONS: Grade 4 events are as important as AIDS events in the era of HAART. To adequately evaluate the impact of HAART on morbidity, comorbidities and other key factors must be carefully assessed.

Entities:  

Mesh:

Year:  2003        PMID: 14615655     DOI: 10.1097/00126334-200312010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  29 in total

1.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Authors:  Jacqueline Neuhaus; Brian Angus; Justyna D Kowalska; Alberto La Rosa; Jim Sampson; Deborah Wentworth; Amanda Mocroft
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

Review 2.  The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.

Authors:  Christina M Wyatt; Carlos Malvestutto; Steven G Coca; Paul E Klotman; Chirag R Parikh
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

Review 3.  Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.

Authors:  Paul Kelly; Haroon Saloojee; Jennifer Y Chen; Raymond T Chung
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Authors:  Lee D Fader; Eric Malenfant; Mathieu Parisien; Rebekah Carson; François Bilodeau; Serge Landry; Marc Pesant; Christian Brochu; Sébastien Morin; Catherine Chabot; Ted Halmos; Yves Bousquet; Murray D Bailey; Stephen H Kawai; René Coulombe; Steven LaPlante; Araz Jakalian; Punit K Bhardwaj; Dominik Wernic; Patricia Schroeder; Ma'an Amad; Paul Edwards; Michel Garneau; Jianmin Duan; Michael Cordingley; Richard Bethell; Stephen W Mason; Michael Bös; Pierre Bonneau; Marc-André Poupart; Anne-Marie Faucher; Bruno Simoneau; Craig Fenwick; Christiane Yoakim; Youla Tsantrizos
Journal:  ACS Med Chem Lett       Date:  2014-01-22       Impact factor: 4.345

5.  Organ Transplantation and HIV Progress or Success? A Review of Current Status.

Authors:  Alan Taege
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

6.  Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.

Authors:  Erika Aaron; Mirjam-Colette Kempf; Shannon Criniti; Ellen Tedaldi; Ed Gracely; Amy Warriner; Ritu Kumar; Laura H Bachmann
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

7.  Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.

Authors:  Vijay P Singh; Gary D Bren; Alicia Algeciras-Schimnich; David Schnepple; Sarah Navina; Stacey A Rizza; Rajinder K Dawra; Ashok K Saluja; Suresh T Chari; Santhi S Vege; Andrew D Badley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-12       Impact factor: 4.052

Review 8.  Evaluation and treatment of the patient coinfected with hepatitis B and HIV.

Authors:  Ellen Kitchell; Mamta K Jain
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

9.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

10.  Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.

Authors:  Emma Crutchlow; Yohannie Miombe; Tom Latham
Journal:  Malawi Med J       Date:  2008-12       Impact factor: 0.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.